[Immunotherapy for refractory viral infections]

Area of Science:

• Immunology
• Virology
• Cell Therapy

Background:

• Antiviral agents face challenges including toxicity, drug resistance, and high costs.
• Virus-specific T-cells (VSTs) present a curative alternative therapy with prolonged efficacy and no drug resistance.
• VSTs can be generated from peripheral blood mononuclear cells stimulated by viral antigens presented by antigen-presenting cells (APCs).

Purpose of the Study:

• To explore Virus-specific T-cell (VST) therapy as a curative treatment for viral infections.
• To evaluate the efficacy and safety of VST therapy, particularly in post-hematopoietic cell transplantation (HCT) settings.
• To assess the potential of VSTs for treating a broader range of pathogens beyond viruses.

Main Methods:

• Separation of VSTs using capture devices.
• Generation of VSTs by stimulating peripheral blood mononuclear cells with viral antigens on APCs.
• APC preparation via transduction with viral antigen-coding plasmids or pulsing with overlapping peptides.

Main Results:

• VST therapy has demonstrated efficacy in drug-non-responsive viral infections post-HCT.
• Studies show VST therapy can be administered without significant severe graft-versus-host disease (GVHD).
• Third-party donor VSTs have been successfully prepared and used for post-HCT viral infections.

Conclusions:

• VST therapy is an effective alternative to conventional antiviral treatments, particularly for post-transplant viral infections.
• The potential exists to expand VST applications to treat infections caused by other pathogens like bacteria and fungi.
• VSTs hold promise for opportunistic infections in other immunocompromised populations in the future.